Taysha Gene Therapies, Inc. Payments for (Proceeds from) Other Investing Activities
Taysha Gene Therapies, Inc. (TSHA) reported Payments for (Proceeds from) Other Investing Activities of -$134.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromOtherInvestingActivities · last filed 2026-08-11
- Taysha Gene Therapies, Inc. payments for (proceeds from) other investing activities for the quarter ending 2025-12-31 was -$3.00K.
- Taysha Gene Therapies, Inc. payments for (proceeds from) other investing activities for the quarter ending 2025-09-30 was -$60.00K.
- Taysha Gene Therapies, Inc. payments for (proceeds from) other investing activities for the quarter ending 2025-06-30 was -$64.00K.
- Taysha Gene Therapies, Inc. payments for (proceeds from) other investing activities for the quarter ending 2025-03-31 was -$7.00K.
- Taysha Gene Therapies, Inc. payments for (proceeds from) other investing activities for fiscal 2025 was -$134.00K.
- Taysha Gene Therapies, Inc. payments for (proceeds from) other investing activities for fiscal 2024 was -$11.00K.
- Taysha Gene Therapies, Inc. payments for (proceeds from) other investing activities for fiscal 2023 was -$17.00K, a 127.87% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. payments for (proceeds from) other investing activities for fiscal 2022 was $61.00K.
| Period end | Payments for (Proceeds from) Other Investing Activities 3 month | Payments for (Proceeds from) Other Investing Activities 6 month | Payments for (Proceeds from) Other Investing Activities 9 month | Payments for (Proceeds from) Other Investing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$63.00K derived: sum of 2 quarters · filed 2026-03-19 | -$127.00K derived: sum of 3 quarters · filed 2026-08-11 | -$134.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | -$60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$124.00K derived: sum of 2 quarters · filed 2026-08-11 | -$131.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | -$64.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$71.00K 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | -$7.00K 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$11.00K 10-K · filed 2026-03-19 | |||
| 2023-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$17.00K 10-K · filed 2025-02-26 | ||
| 2023-09-30 | -$10.00K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $61.00K 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |